Healthcare -
Biotechnology - NASDAQ - US
$ 5.23
0.402 %
$ 9.48 M
Market Cap
-0.26
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Cellectar Biosciences, Inc.
| Current Assets | 24.3 M |
| Cash & Short-Term Investments | 23.3 M |
| Receivables | 0 |
| Other Current Assets | 962 K |
| Non-Current Assets | 1.22 M |
| Long-Term Investments | 0 |
| PP&E | 1.19 M |
| Other Non-Current Assets | 29.8 K |
| Current Liabilities | 9.39 M |
| Accounts Payable | 611 K |
| Short-Term Debt | 84.4 K |
| Other Current Liabilities | 8.69 M |
| Non-Current Liabilities | 1.79 M |
| Long-Term Debt | 410 K |
| Other Non-Current Liabilities | 1.38 M |
EFFICIENCY
Earnings Waterfall
Cellectar Biosciences, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 51.8 M |
| Operating Income | -51.8 M |
| Other Expenses | -7.2 M |
| Net Income | -44.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cellectar Biosciences, Inc.
| Net Income | -44.6 M |
| Depreciation & Amortization | 292 K |
| Capital Expenditures | -104 K |
| Stock-Based Compensation | 4.27 M |
| Change in Working Capital | -1.73 M |
| Others | -5.97 M |
| Free Cash Flow | -47.7 M |
Wall Street Analysts Price Targets
Cellectar Biosciences, Inc.
CLRB has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CLRB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Cellectar Biosciences, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
256 K USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
8.4 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 2 weeks ago
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $6.9 million prior to deducting underwriting commissions and offering expenses. The offering includes participation from healthcare dedicated funds and executive management.
globenewswire.com
- 4 weeks ago
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.
globenewswire.com
- 1 month ago
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Nusano, a physics company transforming the production of radioisotopes, today announced the signing of a multi-year supply agreement in which Nusano will provide Cellectar with iodine-125 (I-125) and actinium-225 (Ac-225) for its clinical studies and future commercial needs.
globenewswire.com
- 1 month ago
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company has submitted a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1b Dose Finding study of its Auger emitting radiopharmaceutical, CLR 125, for the treatment of relapsed TNBC.
globenewswire.com
- 1 month ago
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a one-for-thirty reverse stock split (the “Reverse Stock Split”) of the company's common stock, par value $0.00001, which will become effective at 12:01 a.m. Eastern Time on Tuesday, June 24, 2025. The company's common stock will continue to trade under its current trading symbol, CLRB, on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis when the market opens on Tuesday, June 24, 2025, with the new CUSIP number 15117F880.
globenewswire.com
- 1 month ago
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median
globenewswire.com
- 1 month ago
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million from the sale of shares of the company's common stock priced at-market for Nasdaq purposes. The closing of the offering is expected to occur on or about June 6, 2025, subject to satisfaction of customary closing conditions.
globenewswire.com
- 1 month ago
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer Expected Late July FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for iopofosine I 131, a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM).
globenewswire.com
- 1 month ago
4 Medical Product Stocks to Watch From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
zacks.com
- 2 months ago
Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Jim Caruso - President and CEO Chad Kolean - CFO Jarrod Longcor - COO Anne Marie Fields - IR, Managing Director, Precision AQ Conference Call Participants Aydin Huseynov - Ladenburg Thalmann Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode.
seekingalpha.com
- 2 months ago
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data
globenewswire.com
- 2 months ago
8. Profile
Summary
Cellectar Biosciences, Inc. CLRB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 9.48 M
Dividend Yield
0.00%
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Contact
100 Campus Drive, Florham Park, NJ, 07932
https://www.cellectar.com
IPO
Date
Nov. 10, 2005
Employees
11
Officers
Mr. Jarrod Longcor
Chief Operating Officer
Mr. James V. Caruso
President, Chief Executive Officer & Director
Mr. Chad J. Kolean CPA
Vice President, Chief Financial Officer & Secretary